An anticoagulant rivaroxaban may improve survival free of complications related to portal hypertension in patients with ...

In stable patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with rivaroxaban 20 mg once daily did not improve clinical outcomes but did increase bleeding ...

Rivaroxaban does not seem to be an effective alternative to vitamin K antagonists (VKAs) in patients with antiphospholipid antibody syndrome (APS), an autoimmune disorder, with randomized results ...

Another rivaroxaban perk: it's a one-dose-a-day drug, without the need for constant adjustments. "The best thing is you don't have to get your blood checked.

Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...

A rivaroxaban-based anticoagulation strategy did not improve outcomes and increased bleeding in patients hospitalized with COVID-19 compared with standard hospital prophylaxis, according to data ...

In pediatric patients undergoing the Fontan procedure, those assigned rivaroxaban had numerically lower but statistically similar rates of thrombotic events compared with those assigned aspirin ...

Rivaroxaban (Xarelto, Janssen) received FDA approval today for the prevention of deep vein thrombosis which may lead to a pulmonary embolism in patients undergoing knee or hip replacement surgery ...

Results showed that patients treated with apixaban had a 43% lower risk of ischemic stroke or systemic embolism compared with those who received rivaroxaban (hazard ratio [HR], 0.57; 95% CI, 0.40 ...

Although rivaroxaban was noninferior to warfarin in the pivotal ROCKET trial, warfarin was not used as skillfully in ROCKET as in RE-LY and other recent trials, thereby making it difficult to ...

It comes as a tablet to take by mouth, with or without food. Dosage & When it is to be taken For patients with atrial fibrillation or recent surgery: Take Rivaroxaban 1 time a day with evening meal.

Moreover, rivaroxaban was associated with a significantly lower HRU vs warfarin, including fewer hospitalizations (35.1% vs 38.6% of patients, respectively; OR: 0.86; 95% CI: 0.77, 0.96; P =.0057 ...